Demography and Outcome of Cancer Patients with COVID-19: A Retrospective Cohort Study in Dharmais National Cancer Center Indonesia

Fifi Dwijayanti¹, Chainurridha Chainurridha¹, Ahmad Rusdan Handoyo Utomo²,³, Mururul Aisyi¹, Hubertus Hosti Hayuanta⁴, Jaka Pradipta⁵

¹Research and Development Department, Dharmais Cancer Hospital - National Cancer Center, Jakarta, Indonesia. ²Dharmais Cancer Hospital - National Cancer Center, Jakarta, Indonesia. ³Biomedical Science Universitas YARSI, Jakarta, Indonesia. ⁴Department of Clinical pathology, Dharmais Cancer Hospital - National Cancer Center, Jakarta, Indonesia. ⁵Lung Cancer Research Team, Dharmais Cancer Hospital - National Cancer Center, Jakarta, Indonesia.

Abstract

Introduction: Cancer patients have an increased risk of morbidity and mortality due COVID-19 partly due to their immunocompromised status. We aimed to investigate the associations of clinicopathological factors and survival outcomes in cancer patients with COVID-19. Methods: This was a retrospective cohort study comprised of cancer patients treated in Dharmais National Cancer Center, Indonesia. Main inclusion criteria were pathologically confirmed malignancy with positive results of RTPCR COVID-19 tests. Results: A total of 16,511 visitors had visited and registered for RTPCR test in Dharmais National Cancer Center from May 2020 to January 2021. Logistic regression showed that male gender (p-value = 0.019; OR = 1.732), haematological type of malignancy (p-value <0.001; OR = 3.073), patients not underwent cancer therapy (p-value = 0.008; OR = 0.485), low RTPCR Ct values (p-value = <0.001; OR = 3.340), poor performance status (p-value = <0.001; OR = 8.194), and disease severity (p-value = <0.001; OR = 5.448) were associated with mortality. Conclusion: Overall mortality rate in Dharmais cancer patients (25%) was higher than other cancer patients treated in other hospitals in Asia. Moreover, the mortality rate was similar across all age groups. Poor survival in young age might be explained by the fact that median age of cancer patients was 46 years old. In addition to male gender, cancer patients with low Ct values and having delayed cancer treatment were vulnerable groups of having poor outcomes when diagnosed with COVID-19. Long-term follow-up is required to examine the survival rate in cancer patients with COVID-19.

Keywords: COVID-19- Cancer- Survival- Demography- Mortality

Introduction

Currently, the world is struggling with a global pandemic of coronavirus disease 2019 (COVID-19). World Health Organization (WHO) stated it as a pandemic on March 11, 2020 [1]. Globally, there were 190,671,330 confirmed cases of COVID-19, including 4,098,758 deaths, reported to WHO on July 21, 2021 [2]. During this period, Indonesia had recorded more than 1 million positive cases and 76,200 death cases [3]. While worldwide preventive measures have been ongoing, number of new cases continue to rise and pose persisting threat to all populations, including cancer patients. Patients with cancer had a high risk of contracting severe COVID-19 and with a poorer prognosis than those without cancer [4].

During the pandemic, cancer patients are caught as a unique group with an increased risk of contracting COVID-19 partly due to their immunocompromised condition [4]. Their weakened immunity is resulting from many factors including the malignancy burden and ongoing treatment such as surgery, chemotherapy,
radiotherapy, or even due to patients undergoing transplant and use of immunosuppressants [5]. This pandemic has created dilemmas and unpredictable impacts on cancer management which include diagnostic work-ups, treatment schedules, and follow-up visits. The isolation of patients infected with COVID-19 has caused losing valuable clinic visits. New patients could miss an early diagnosis which may lead to worse prognosis. In addition, patients with advanced cancer may have to postpone treatments risking disease progression [6].

Low-and middle-income countries (LMIC) with ailing healthcare systems are more vulnerable to contain the pandemic, especially in efforts to manage cancer patients. Dharmais National Cancer Center in Indonesia has deployed strict mitigation system in order to minimize exposure of viral transmission to healthcare providers and patients to and to optimize cancer management [7]. Our current study analyzed associations of clinical characteristics and outcomes of cancer patients with COVID-19 in Dharmais.

Materials and Methods

Study design and participants

This was a retrospective cohort study to estimate demographic and clinical factors associated with outcome of cancer patients with COVID-19 in National Cancer Center, Indonesia. COVID-19 incidents were obtained from SARS-CoV-2 reverse transcribed polymerase chain reaction (RT-PCR) test records of patients registered in medical database of Dharmais Cancer Hospital between May 01, 2020 to January 31, 2021. Based on Indonesia’s national COVID-19 management guidelines [8], Dharmais conducted confirmatory SARS-CoV-2 RTPCR test on nasopharyngeal and/or oropharyngeal swabs specimens in the laboratory. Cancer patients were discharged or proceeded to cancer treatment after demonstrating negative test results of two consecutive RT-PCR tests, or being declared free of COVID-19 by pulmonologist-in-charge.

The population in this study were all patients who were treated in and registered at the Dharmais Cancer Hospital. The eligibility criteria were (1) patients with confirmed cancer diagnosis by pathologists or other supporting results in medical records and (2) had positive SARS-CoV-2 RTPCR-positive tests. Patients with suspected or absent of malignancy were excluded.

Data collection and variables

Data were extracted from hospital medical record of RT-PCR test results. All patients with RT-PCR-positive test results were taken and then evaluated by pathologists to confirm cancer diagnosis. Subsequently, patient demographics (age and gender), clinical characteristics, cancer management, clinical history of COVID-19 treatment, and outcomes were collected. The clinical characteristics included type of malignancy, symptoms, comorbidity, performance status, RT-PCR Cycle Threshold Value (Ct value), and disease severity. We categorized cancer treatment status into treatment naïve and previously treated patients and type of cancer management (diagnostic biopsy, evaluation, stabilized clinical condition, as well as having targeted therapy, chemotherapy, surgery, radiotherapy, chemoradiation, and others). Lastly, clinical outcome indicated the number of patients who survived or died. Death cases were patients who died of any cause within 30 days of confirmed COVID-19 diagnosis.

Symptoms and comorbidities were collected from patient self-questionnaires. We used The Eastern Cooperative Oncology Group (ECOG) score to measure performance status cancer patients with COVID-19. The ECOG score was ran from 0 to 5, with 0 denoting perfect health and 5 death [9].

This study distinguished in-patients and out-patients to determine the differences in demographic and clinical characteristics of patients between these groups. In-patients indicated that the patient was infected with COVID-19 while undergoing treatment in the hospital wards. On the other hand, outpatients were all patients who had any symptoms of COVID-19, confirmed by RT-PCR who were about to undergo any cancer management modalities. Cancer therapy was divided into two categories i.e. having chemotherapy or no chemotherapy. Surgery, radiotherapy, diagnostics, and treatment for stabilized clinical conditions were included in the non-chemotherapy category.

We also measured COVID-19 disease severity. The Ministry of Health Indonesia classified the disease severity of COVID-19 into four groups, namely asymptomatic or mild, moderate, severe, and critical conditions. Mild symptom is a condition without evidence of viral pneumonia or without hypoxia. Symptoms include fever, cough, fatigue, anorexia, shortness of breath, myalgia. Other non-specific symptoms such as sore throat, nasal congestion, headache, diarrhea, nausea and vomiting, smell (anosmia), or loss of taste (ageusia) [10].

Moderate symptoms in adolescent or adult patients included pneumonia (fever, cough, shortness of breath, rapid breathing) but no signs of severe pneumonia including SpO_{2} <93% with room air. In children, it showed symptoms of non-severe pneumonia (coughing or difficulty breathing, rapid breathing, and/or chest wall traction) and no signs of severe pneumonia [10].

In adolescent or adult patients, severe symptoms showed the symptoms of pneumonia (fever, cough, shortness of breath, rapid breathing) and/or respiratory rate > 30 bpm, severe respiratory distress, or SpO_{2} <93% in room air. Lastly, critical symptoms comprised of Acute Respiratory Distress Syndrome (ARDS), sepsis, and septic shock [10].

There were two types of PCR assay available at our hospital, namely open system and closed system PCR. Open system PCR in our hospital is using QIAasympohony DSP Virus/Pathogen mini kit (Qiagen, Germany) for extraction reagent kit, LightMix Modular SARS-CoV-2 (COVID-19) (Roche, Germany) for amplification reagent kit, and Rotor Gene Q (Qiagen, Germany) for real time PCR cycler. Target genes for this open system PCR were E and RdRp gene as target genes with CT cut off point 36 and
Patients were respiratory (cough, shortness of breath, fever) and gastrointestinal (nausea, vomiting, and diarrhea). The inpatients disease severity and mortality were also higher than outpatients. Mortality rate in hematological cancer was also higher than solid tumors. Based on type of malignancy, hematological mortality was higher than solid tumors, lung cancer and nasopharyngeal cancer were the highest deaths in solid tumors, AML was the highest mortality in hematology (Figure 1). Chemotherapy was the most frequent modality of cancer management (Figure 2).

Logistic regression showed that gender (p-value = 0.019; OR = 1.732, 95% CI OR = 1.095-2.739), type malignancy (p-value = <0.001; OR = 3.340, 95% CI OR = 1.920-5.747), performance status (p-value = <0.001; OR = 5.448, 95% CI OR = 3.916-7.578) were associated with mortality. We did adjustments in therapy cancer and status performance to confirmed the number of deaths in patients with ECOG score ≤ 2. The results showed that mortality in patients who did not undergo chemotherapy was higher than those patients were respiratory (cough, shortness of breath, fever) and gastrointestinal (nausea, vomiting, and diarrhea). The inpatients disease severity and mortality were also higher than outpatients. Mortality rate in haematological cancer was also higher than solid tumors. Based on type of malignancy, hematological mortality was higher than solid tumors, lung cancer and nasopharyngeal cancer were the highest deaths in solid tumors, AML was the highest mortality in hematology (C).

Figure 1. Outcome of Cancer Patients with COVID-19. Based on Type of Malignancy. Hematological Mortality was Higher than Solid Tumors (A), Lung Cancer and Nasopharyngeal Cancer were the Highest Deaths in Solid Tumors (B), AML was the Highest Mortality in Hematology (C).
| Variables | Total (%) | Inpatient (%) | Outpatient (%) |
|-----------|-----------|---------------|----------------|
| (N = 403) | (N = 170) | (N = 233) |
| Median Age, (min-max) years | 46 (5 - 73) | 46 (5 - 73) | 48 (7 - 77) |
| Gender | | | |
| Male | 148 (36.7) | 78 (52.7) | 70 (47.3) |
| Female | 225 (63.3) | 92 (36.1) | 163 (63.9) |
| Type of malignancy | | | |
| Solid tumors | 339 (84.1) | 124 (36.6) | 215 (63.4) |
| Breast cancer | 110 (27.3) | 30 (27.3) | 80 (72.7) |
| Lung cancer | 28 (6.9) | 16 (57.1) | 12 (42.9) |
| Nasopharyngeal cancer | 22 (5.5) | 9 (40.9) | 13 (59.1) |
| Cervical cancer | 28 (6.9) | 9 (32.1) | 19 (67.9) |
| Colorectal cancer | 36 (8.9) | 11 (30.6) | 25 (69.4) |
| Others | 112 (27.8) | 48 (42.9) | 64 (57.1) |
| Hematology | | | |
| ALL | 13 (3.2) | 10 (76.9) | 3 (23.1) |
| Lymphoma | 22 (5.5) | 10 (45.5) | 12 (54.5) |
| AML | 18 (4.5) | 15 (83.3) | 3 (16.7) |
| Others | 14 (3.5) | 12 (85.7) | 2 (14.3) |
| Symptoms | | | |
| Asymptomatic | 180 (44.7) | 15 (8.3) | 165 (91.7) |
| Symptomatic | 223 (55.3) | 155 (69.5) | 68 (30.5) |
| Respiratory | 167 (41.4) | 115 (68.9) | 52 (31.1) |
| Gastrointestinal (GI) | 12 (3.0) | 6 (50.0) | 6 (50.0) |
| Respiratory and GI | 36 (8.9) | 32 (88.9) | 4 (11.1) |
| Others | 8 (2.0) | 2 (25.0) | 6 (75.0) |
| Comorbidity | | | |
| Malignancy alone | 319 (79.2) | 136 (42.6) | 183 (57.4) |
| Additional comorbidity | | | |
| Hypertension | 44 (10.9) | 18 (40.9) | 26 (59.1) |
| Heart failure | 7 (1.7) | 4 (57.1) | 3 (42.9) |
| Diabetes | 10 (2.5) | 4 (40.0) | 6 (60.0) |
| Multiple comorbidity | 23 (5.7) | 8 (34.8) | 15 (65.2) |
| Ct value (median, min-max)* | 17.17 (2.81 – 31.33) | 14.38 (2.81-30.95) | 18.00 (3.42-31.33) |
| Therapy status | | | |
| Treatment naïve | 168 (41.7) | 93 (55.4) | 75 (44.6) |
| Previously treated | 74 (18.4) | 41 (55.4) | 33 (44.6) |
| Ongoing therapy | 161 (40.0) | 99 (61.5) | 62 (38.5) |
| Cancer management | | | |
| Diagnostic biopsy | 58 (14.4) | 18 (31.0) | 40 (69.0) |
| Routine Evaluation | 36 (8.9) | 5 (13.9) | 31 (86.1) |
| Stabilized clinical condition | 48 (11.9) | 45 (93.8) | 3 (6.3) |
| Targeted therapy | 1 (0.2) | 1 (100.0) | 0 (0.0) |
| Chemotherapy | 122 (30.3) | 41 (33.6) | 81 (66.4) |
| Surgery | 31 (7.7) | 21 (67.7) | 10 (32.3) |
| Radiotherapy | 35 (8.7) | 12 (34.3) | 23 (65.7) |
| Chemoradiation | 6 (1.5) | 4 (66.7) | 2 (33.3) |
| Others | 66 (16.4) | 23 (34.8) | 43 (65.2) |
Continued Table 1.

| Variables                              | Total (%) (N = 403) | Inpatient (%) (N = 170) | Outpatient (%) (N = 233) |
|----------------------------------------|---------------------|-------------------------|--------------------------|
| Performance status (ECOG)              |                     |                         |                          |
| 0                                      | 103 (25.6)          | 10 (9.7)                | 93 (90.3)                |
| 1                                      | 138 (34.2)          | 42 (30.4)               | 96 (69.6)                |
| 2                                      | 92 (22.8)           | 57 (62.0)               | 35 (38.0)                |
| 3                                      | 48 (11.9)           | 41 (85.4)               | 7 (14.6)                 |
| 4                                      | 22 (5.5)            | 20 (90.9)               | 2 (9.1)                  |
| COVID-19 disease grade                 |                     |                         |                          |
| Asymptomatic                           | 180 (44.7)          | 15 (8.3)                | 165 (91.7)               |
| Mild                                   | 69 (17.1)           | 6 (8.7)                 | 63 (91.3)                |
| Moderate                               | 54 (13.4)           | 52 (96.3)               | 2 (3.7)                  |
| Severe                                 | 96 (23.8)           | 93 (96.9)               | 3 (3.1)                  |
| Critical                               | 4 (1.0)             | 4 (100.0)               | 0 (0.0)                  |
| Outcomes                               |                     |                         |                          |
| Survive                                | 302 (74.9)          | 78 (25.8)               | 224 (74.2)               |
| Deceased                               | 101 (25.1)          | 92 (91.1)               | 9 (8.9)                  |

Table 2. SARS-CoV-2 RTPCR Ct Values Based on Several Assays

| Ct value     | n   | Ct value Cut off | Mean | Median | Min - Max |
|--------------|-----|------------------|------|--------|-----------|
| Abbott*      | 365 | 31.6             | 16.52| 17.17  | 2.81 – 31.33 |
| GeneXpert E  | 8   |                  | 27.4 | 26.85  | 16.20 – 42.80 |
| N2           | 45  | 30.1             | 29.4 |        | 18.70 – 38.80 |
| Qiagen E     | 20  | 36               | 25.48| 27.78  | 10.90 – 33.47 |
| RdRP         |     | 41               | 28.75| 31.37  | 11.49 – 38.63 |

*based on Abbott Ct value

Figure 2. Cancer Management in COVID-19 Patients. Chemotherapy is the most common cancer management when patients diagnosed with COVID-19.

Discussion

Given the wide range in disease course for COVID-19, the ability to predict which cancer patients are at particularly high risk of deterioration and negative outcomes would be of particular value in the clinical setting. Our study found five risk factors that were significantly associated with mortality in cancer patients with COVID-19, i.e. gender, type malignancy, RTPCR Ct values, performance status, and COVID-19 disease severity. Demographic factors and clinical characteristics are important in predicting mortality.

This study investigated the association of age and gender to mortality in cancer patients with COVID-19. The results showed that age was not significant risk factor of mortality and had been showed by previous studies [11,12]. The median age in cancer patients was lower (46 years old) than the general population (50 years old) in Indonesia [13] and over 50 years old in globally [14,15]. In Asia Pacific (China, Singapura, Korea, and Australia) [16-18], Europe (Italy, Spain, France, and United Kingdom) [19-22], and America (USA and Brazil) [23,24] has a median aged more than 60 years [25]. Our data suggest that vulnerability of cancer patients to high risk of mortality was independent of age.

In our cohort, male cancer patients had higher risk of COVID-19 mortality than female patients. Females and males have differences in their susceptibility and response to viral infections, leading to gender differences in the
incidence and severity of the disease [26]. However, and likely in association with differences in the incidence of poor condition, risky and preventive behaviours, or immune systems, male gender was overrepresented among COVID-19 fatalities. This observation was consistent with recent data from China, Spain, and Italy regarding the COVID-19 outbreak showed that the percentage of males who have died due to the infection was much higher than

| Variables                     | Survive (%) | Deceased (%) | Sig     | OR     | 95% CI OR |
|-------------------------------|-------------|--------------|---------|--------|-----------|
| Age                           |             |              |         |        |           |
| < 50                          | 165 (74.7)  | 56 (25.3)    | 0.649   | 0.94   | 0.721-1.226 |
| 50 – 59                       | 79 (74.5)   | 27 (25.5)    |         |        |           |
| 60 – 69                       | 45 (73.8)   | 16 (26.2)    |         |        |           |
| > 70                          | 13 (86.7)   | 2 (13.3)     |         |        |           |
| Gender                        |             |              |         |        |           |
| Female                        | 201 (78.8)  | 54 (21.2)    | 0.019 * | 1.732  | 1.095-2.739 |
| Male                          | 101 (68.2)  | 47 (31.8)    |         |        |           |
| Types of malignancy           |             |              |         |        |           |
| Solid tumor                   | 267 (78.8)  | 72 (21.2)    | <0.001 *| 3.073  | 1.761-5.362 |
| Haematology                   | 35 (54.7)   | 29 (45.3)    |         |        |           |
| Comorbidity                   |             |              |         |        |           |
| No comorbidity                | 238 (74.6)  | 81 (25.4)    | 0.672   | 1.046  | 0.850-1.287 |
| Additional comorbidity besides malignancy | | | | | |
| Hypertension                  | 37 (84.1)   | 7 (15.9)     |         |        |           |
| Heart failure                 | 3 (42.9)    | 4 (57.1)     |         |        |           |
| Diabetes                      | 8 (80.0)    | 2 (20.0)     |         |        |           |
| Double comorbidity            | 16 (69.6)   | 7 (30.4)     |         |        |           |
| Therapy status                |             |              |         |        |           |
| Treatment naive               | 121 (72.0)  | 47 (28.0)    | 0.193   | 0.846  | 0.659-1.088 |
| Previously treated            | 55 (74.3)   | 19 (25.7)    |         |        |           |
| Ongoing therapy               | 126 (78.3)  | 35 (21.7)    |         |        |           |
| Ct value#                     |             |              |         |        |           |
| Abbott (median = 17.17)       |             |              |         |        |           |
| ≥ median                      | 159 (86.9)  | 24 (13.1)    | <0.001 *| 3.34   | 1.970-5.664 |
| < median                      | 121 (66.5)  | 61 (33.5)    |         |        |           |
| GeneXpert (median = 26.85)    |             |              |         |        |           |
| < median                      | 2 (50.0)    | 2 (50.0)     | 0.429   | 0.5    | 0.188-1.332 |
| ≥ median                      | 0 (0.0)     | 4 (100.0)    |         |        |           |
| Qiagen (median = 31.37)       |             |              |         |        |           |
| < median                      | 9 (60.0)    | 6 (40.0)     | 0.613   | 0.375  | 0.033-4.228 |
| ≥ median                      | 4 (80.0)    | 1 (20.0)     |         |        |           |
| Performance status            |             |              |         |        |           |
| ECOG ≤ 2                      | 276 (82.9)  | 57 (17.1)    | <0.001 *| 8.194  | 4.669-14.381 |
| ECOG >2                       | 26 (37.1)   | 44 (62.9)    |         |        |           |
| ECOG ≤ 2 not chemotherapy     | 179 (80.3)  | 44 (19.7)    | 0.074   | 0.545  | 0.280-1.061 |
| chemotherapy                  | 97 (88.2)   | 13 (11.8)    |         |        |           |
| Disease severity              |             |              |         |        |           |
| Asymptomatic                  | 174 (96.7)  | 6 (3.3)      | <0.001 *| 5.448  | 3.916-7.578 |
| Mild                          | 66 (95.7)   | 3 (4.3)      |         |        |           |
| Moderate                      | 39 (72.2)   | 15 (27.8)    |         |        |           |
| Severe                        | 23 (24.0)   | 73 (76.0)    |         |        |           |
| Critical                      | 0 (0.0)     | 4 (100.0)    |         |        |           |

#based on Abbott; * Significance < 0.05; OR, Odds Ratio
females [27]. In China, for example, found that the fatality rate among men with the virus was about 65% higher than among women. A study in 177 countries and territories suggested that more consideration should be paid to male patients, particularly those over 65 years old for enhanced clinical management [25].

Cancer patients are particularly susceptible to respiratory pathogens and severe pneumonia, because they are at an immunosuppressive state due to malignancy and anticancer therapy. Nearly half of haematological malignancy had high death rates in this study. One of the reasons why outcomes may be worse in patients with haematological malignancies is that in many cases, immune responses to the virus are less pronounced and highly variable compared with people with other types of cancer, with delayed or negligible seroconversion, prolonged viral shedding, and sustained immune dysregulation [28]. Lower respiratory tract diseases caused by human coronaviruses in patients with haematological malignancies have been associated with high rates of oxygen use and mortality [29]. Solid tumor on the other hand had good prognoses. More than half solid tumor patients survived from COVID-19.

Cancer management such as chemotherapy, surgery, and radiotherapy protocols may suppress immune system, which may lead to worsening of COVID-19 associated morbidity and/or mortality [30]. Furthermore, cancer patients who were being diagnosed with COVID-19 may also risk cancer progression which may jeopardize a chance of survival [31]. However, there was no strong association between status of cancer therapy and mortality within this study cohort.

Cancer therapy can cause a weakened immune system, including chemotherapy. The first objective of using chemotherapy is to kill cancer cells. Chemotherapy can also affect immune cells and thus contribute not only to effective tumor response but also to tumor resistance [32]. Chemotherapy can cause neutropenia (decreased number of neutrophils, a type of white blood cell). This means the body may not be able to fight infection properly. While chemotherapy may affect survival of blood cancer patients with COVID, others studies show that chemotherapy may not imposed additional survival risk [33,34].

Cancer patients with COVID-19 had delayed treatment because they have to be quarantined for approximately 14 days or more. Delayed treatment of cancer can make adverse consequences on outcome. A four-week delay in treatment was associated with an increased risk of death. For surgery, 6-8% increased risk of death for every four-week delay. This effect was even more marked in some radiotherapy and systemic indications, with an increased risk of death of 9% and 13% for definitive head and neck radiotherapy and adjuvant systemic treatment for colorectal cancer, respectively [35]. Therefore, our data may indicate that the increased rate of mortality in patients who did not undergo chemotherapy may die due to malignancy instead of COVID-19. At this stage we could not distinguish the death of COVID-19 or of malignancy.

The cycle threshold (Ct) value is the number of cycles of amplification to detect the virus genetic materials. It is an estimate of how much virus was likely in the sample to start with – instead of the actual number of viable virus particles. If the virus is found in a low number of cycles (Ct value under 30), it means that the virus was easier to find in sample and that the sample started out with a large amount of the virus [36]. Clinical knowledge of COVID-19 is constantly evolving, with studies being published at a high rate; however, there is currently only limited data relating to the correlation of viral loads with patient prognoses, such as mortality or disease progression. A study reported on the association between mortality and SARS-CoV-2 Ct value and showed that lower Ct values correlated with increased risk of death, [37] which is consistent with data for previous epidemic-causing coronaviruses [38,39].

Many studies reported on the correlation of Ct values with symptom severity that indicated that lower Ct values were associated with more severe disease. This is consistent with some previous studies of Ct values in other respiratory infections, although other studies do not show correlation [40]. The limitation of our study, we did not perform quantitative measurement of viral particles in laboratory culture and correlate with Ct values.

Lastly, patients with ECOG > 2 had 8 times risk for death. We did an adjustment and the data showed in this category the patients were doing ‘not chemotherapy’ category and stabilized the clinical condition. In Dharmais Hospital as a tertiary hospital. So, the patients that came to us more likely had poor prognostic. For the patient that came for diagnostic, the moment they got COVID-19, we had to delayed any action or treatment for the cancer.

In conclusion, when exposed to COVID-19, cancer patients had higher mortality rate than general population. Gender as demographics factors has association with mortality significantly. Clinical characteristics such as type malignancy, Ct value, performance status, and disease severity were associated with mortality. COVID-19 had a huge impact on cancer treatment and management. Cancer patients with COVID-19 would postpone doctor visits, diagnostic work-up, chemotherapy, and others which can increase the risk of mortality. Further research is required to investigate the others factor of infection COVID-19 such as body mass index (BMI), blood type, smoking history and examine the survival rate in cancer patients with COVID-19.

Acknowledgments

We would like to thank all the COVID-19 mitigation team in Dharmais National Cancer Center, Jakarta, Indonesia.

Conflict Of Interest

The authors report no conflict of interest

References

1. World Health Organization. Coronavirus disease (COVID-19) pandemic [Internet]. Coronavirus disease. 2020 [cited 2021 July 21]. Available from: https://www.who.int/emergencies/
1. World Health Organization. WHO Coronavirus (COVID-19) [Internet]. Coronavirus disease. 2021 [cited 2021 July 21]. Available from: https://covid-19.who.int/

2. Satuan Tugas COVID-19. Data Sebaran Situasi virus COVID-19 [Internet]. 2020 [cited 2021 July 21]. Available from: https://covid-19.go.id/

3. Ministry of Health. Guidelines for the prevention and control of coronavirus disease COVID-19. 4th edition. Jakarta: Ministry of Health Indonesia; 2020:1-35.

4. Y X, R J, J Z, W L, H S. Risk of COVID-19 for patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. The Aging Male: The Official Journal of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology: Cancer Clinical Trials. 1982;5:649-55.

5. A. Alenazi TH, Alhejazi A, Al Safi F, Al Olayan A. Risk of COVID-19 for patients with Coronavirus disease 2019 (COVID-19): A Multicenter Study across Saudi Arabia. JCO global oncology. 2020 03;6:471-475. https://doi.org/10.1200/JCO.20.00064

6. Wang Z, Wang J, He J. Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China. JAMA oncology. 2020 05 01;6(5):631-632. https://doi.org/10.1001/jamaoncol.2020.1198

7. Dwijayanti F, Setiadi H, Makful M. COVID-19 and Cancer Care in Indonesia: What we have done in Dharmasri Cancer Center Hospital. Indonesian Journal of Cancer. 2020 07 01;14:37. https://doi.org/10.33371/jioc.v14i2.747

8. Ministry of Health. Guidelines for the prevention and control of coronavirus disease COVID-19. 4th edition. Jakarta: Ministry of Health Indonesia; 2020:1-35.

9. Oken M, Creech R, Davis T. Toxicology and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology: Cancer Clinical Trials. 1982;5:649-55.

10. Burhan E, Susanto A, Nasution S, Ginanjar E, Pitoyo C, Susilo A, et al. Guidelines of COVID-19 Management. Third edition. Jakarta: Ministry of Health Indonesia; 2020:3-6:88-9.

11. Parohon M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. The Aging Male: The Official Journal of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology: Cancer Clinical Trials. 1982;5:649-55.

12. Zariklar P, Kamath A, Robinson C, Morgulich N, Shah SFH, Cheng TKM, Dominic C, Fehintola AO, Bhalla G, Ahillan T, Mouarge d’Algue L, Lee J, Pareek A, Carey M, Hughes DJ, Miller M, Woodcock VK, Shrotri M. Clinical Characteristics and Outcomes in Patients with COVID-19 and Cancer: A Systematic Review and Meta-analysis. Journal of Clinical Oncology. 2020 07;28(21):3021-7. https://doi.org/10.1001/jco.2020.0598

13. Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adiuan V, Widastuti N, Oktavia D, Tankia S, Lina RN, Andrianto A, Lestari KD, Burhan E, Shankar AH, Thwaites G, Baird JK, Hamers RL. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. The Lancet Regional Health. Western Pacific. 2021 04;9:100108. https://doi.org/10.1016/j.lanwpc.2021.100108

14. Abdihmid O, Cai C, Kapesa L, Zeng S. The Landscape of COVID-19 in Cancer Patients: Prevalence, Impacts, and Recommendations. Cancer Management and Research. 2020;12:8923-8933. https://doi.org/10.2147/CMAR.S27008

15. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F, Lu Y, Liu X, Chen Y, Li X, Li Y, Summah HD, Lin H, Yan J, Zhou M, Lu H, Qu J. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. American Journal of Respiratory and Critical Care Medicine. 2020 06 01;201(11):1380-1388. https://doi.org/10.1164/rcmm.2020-0445OC

16. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, Xiong Y, Xiong H, Wang C, Chen C, Xiong F, Zhang Y, Peng Y, Ge S, Zhen B, Yu T, Wang L, Wang H, Liu Y, Chen Y, Mei J, Gao X, Li Z, Gan L, He C, Li Z, Shi Y, Qi Y, Yang J, Tenen DG, Chai L, Mucci LA, Santillana M, Cai H. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discovery. 2020 06;10(6):783-791. https://doi.org/10.1158/2159-8290.CD-20-0422

17. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England). 2020 02 15;395(10223):507-513. https://doi.org/10.1016/S1470-2045(20)30211-7

18. O’Reilly GM, G, Mitchell RD, R, Wu J, J, Rajiv P, P, Bannon- Murphy H, H, Amos T, T, et al. Epidemiology and Clinical Features of Emergency Department Patients with Suspected COVID-19: Initial Results from the COVID-19 Emergency Department Quality Improvement Project (COVID-2) [Internet]. Emergency Medicine Australasia. 2020 [cited 2021 May 29]. Available from: https://search.bvsalud.org/ global-literature-on-novel-coronavirus-2019-ncov/resource/ fr/covidwho-603489?lang=en.

19. Grasselli G, Zaninotto A, Zorella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A, Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 04 28;323(16):1574-1581. https://doi.org/10.1001/jama.2020.5394

20. Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, González E, Polanco N, Folqueira MD, Lalaeza A, Lumbreras C, Agudo JM. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2020 07;20(7):1849-1858. https://doi.org/10.1111/ajt.15929

21. Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography. Radiology. 2020 09;296(2):E186-E188. https://doi.org/10.1148/radiol.202021544

22. Lovell N, Maddocks M, Etikind SN, Taylor K, Carey I, Vora V, Marsh L, Higginson UJ, Prentice W, Edmonds P, Sleeman KE. Characteristics, Symptom Management, and Outcomes of 101 Patients With COVID-19 Referred for Hospital Palliative Care. Journal of Pain and Symptom Management. 2020 07;60(1):e77-e81. https://doi.org/10.1016/j.jpainsymman.2020.04.015

23. Duanyu M, Brown IP, Gibb WR, Singh J, Matheson LW, Blomkalns AL, Govindarajan P. Characteristics of Emergency Department Patients With COVID-19 at a Single Site in Northern California: Clinical Observations and Public Health Implications. Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine. 2020 06;27(6):505-509. https://doi.org/10.1111/acem.14003

24. Paules CI, Marston HD, Fauci AS. Coronavirus Infections—More Than Just the Common Cold. JAMA. 2020 02 25;323(8):707-708. https://doi.org/10.1001/jama.2020.0757

25. Hu D, Lou X, Meng N, Li Z, Teng Y, Zou Y, Wang F.
Influence of age and gender on the epidemic of COVID-19: Evidence from 177 countries and territories—an exploratory, ecological study. Wiener Klinische Wochenschrift. 2021 04;133(7-8):321-330. https://doi.org/10.1007/s00508-021-01816-z

26. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biology of Sex Differences. 2020 05 25;11:29. https://doi.org/10.1186/s13293-020-00304-9

27. Paz C D, Mulle M, Boudet A, Gaddis I. Gender dimension of the COVID-19 pandemic. Gend Dimens COVID-19 pandemic. 18(April). 2020. 964-9.

28. Abdul-Jawad S, Bae L, Alaghuturai T, Molino del Barrio I, Paino LM, Gaddis I, Zackowski K, Tubergen C, Morgan R, Chen J, Lwin Y, Fields P, Karagiannis SN, Green AC, Rigg A, Khan AA, Rowley M, Benjamin R, Enting D, Alrifai D, Al-Rawas B, hazelwood HK, Morgan R, Chavda SJ, Kumar EA, David K, Tomkins O, Sanchez MW, Rivera DR, Shamaa O, Peiris JS, Yuen K. Initial viral load and the outcomes of SARS. CMAJ: Canadian Medical Association Journal. 2004 Nov 23;171(11):1349-1352. https://doi.org/10.1503/cmaj.1040398

29. Ogimi C, Waghmare AA, Kuypers JM, Xie H, Yeung CC, Abdul-Jawad S, Baù L, Alaguthurai T, Molino del Barrio I, Paino LM, Gaddis I, Zackowski K, Tubergen C, Morgan R, Chen J, Lwin Y, Fields P, Karagiannis SN, Green AC, Rigg A, Khan AA, Rowley M, Benjamin R, Enting D, Alrifai D, Al-Rawas B, hazelwood HK, Morgan R, Chavda SJ, Kumar EA, David K, Tomkins O, Sanchez MW, Rivera DR, Shamaa O, Peiris JS, Yuen K. Initial viral load and the outcomes of SARS. CMAJ: Canadian Medical Association Journal. 2004 Nov 23;171(11):1349-1352. https://doi.org/10.1503/cmaj.1040398

30. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Sato K, Liu Y, Yoshida T, Hiyama T, Takahashi K, Tsuda M, Muruganesu N, Newson-Davis T, Olsson-Brown AC, Palles C, Pan Y, Pettengell R, Powles T, Proctor AE, Purshouse K, Sharma-Oates A, Sivakumar S, Smith AJ, Starkey T, Turnbull CD, Varnai C, Yousaf N, Kerr R, Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet (London, England). 2020 06 20;395(10241):1919-1926. https://doi.org/10.1016/S0140-6736(20)31173-9

31. Seth G, Sethi S, Bhattarai S, Saini G, Singh CB, Aneja AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Logan B, Masters T, McKay RR, Mesa RA, Morgans AJ, Starkey T, Turnbull CD, Varnai C, Yousaf N, Kerr R, Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet (London, England). 2020 06 20;395(10241):1919-1926. https://doi.org/10.1016/S0140-6736(20)31173-9

32. Rébé C, Ghiringhelli F. Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?. Future Oncology (London, England). 2015 10;11(19):2645-2654. https://doi.org/10.2217/fon.15.198

33. Fox TA, Troy-Barnes E, Kirkwood AA, Chan WY, Day JW, Chawda SJ, Kumar EA, David K, Tomkins O, Sanchez E, Scully M, Khwaja A, Lambert J, Singer M, Roddie C, Morris EC, Yong KL, Thomson KJ, Ardesna KM. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemotherapy or immunotherapy. British Journal of Haematology. 2020 0ct;191(2):194-206. https://doi.org/10.1111/bjh.17027

34. Lee LY, Cazier J, Angelis V, Arnold R, Bish V, Campton NA, Crackathayil J, Cheng VW, Curley HM, Fitall MW, Freeman-Mills L, Gennatas S, Goel A, Hartley S, Hughes DJ, Kerr D, Lee AJ, Lee RJ, McGrath SE, Middleton CP, Muruganesu N, Newson-Davis T, Olsson-Brown AC, Palles C, Pan Y, Pettengell R, Powles T, Proctor AE, Purshouse K, Sharma-Oates A, Sivakumar S, Smith AJ, Starkey T, Turnbull CD, Varnai C, Yousaf N, Kerr R, Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet (London, England). 2020 06 20;395(10241):1919-1926. https://doi.org/10.1016/S0140-6736(20)31173-9

35. Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, O’Sullivan DE, Booth CM, Sullivan R, Aggarwal A. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ (Clinical research ed.). 2020 Nov 04;371:m4087. https://doi.org/10.1136/bmj.m4087

36. Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, Ghisetti V, Bertucci R, Picco C, Bonora S, Di Perri G, Calcagno A. Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. Viruses. 2021 02 11;13(2):281. https://doi.org/10.3390/v13020281

37. Huang J, Ran R, Lv Z, Feng L, Ran C, Tong Y, et al. Chronological Changes of Viral Shedding in Adult Inpatients with COVID-19 in Wuhan, China. Jinf-Tao. Clinic Infect Dis. 2020 46(May):1-17.

38. Chu C, Poon LL, Cheng VC, Chan K, Hung IF, Wong MM, Chan K, Leung W, Tang BS, Chan VL, Ng W, Sim T, Ng P, Law K, Tse DM, Peiris JS, Yuen K. Initial viral load and the outcomes of SARS. CMAJ: Canadian Medical Association Journal. 2004 Nov 23;171(11):1349-1352. https://doi.org/10.1503/cmaj.1040398

39. Feikin DR, Alraddabiti B, Qurban A, Oboho IK, Tomczyk SM, Wolff B, Watson JT, Madani TA. Association of Higher MERS-CoV Virus Load with Severe Disease and Death, Saudi Arabia, 2014. Emerging Infectious Diseases. 2015 Nov;21(11):2029-2035. https://doi.org/10.3201/eid2111.150764

40. Feikin DR, Wu X, Park DE, Shi Q, Higdon MM, Baggett HC, Brooks WA, Deloria Knoll M, Hammitt LL, Howie SRC, Aggarwal A. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ (Clinical research ed.). 2020 Nov 04;371:m4087. https://doi.org/10.1136/bmj.m4087

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.